Effective Initial Treatment for Follicular Non-Hodgkin's Lymphoma (NHL)

The Goal of RITUXAN Plus CVP* Chemotherapy as an Initial Treatment: Control Follicular Non-Hodgkin's Lymphoma for Longer

RITUXAN can be used along with CVP chemotherapy as an initial treatment for follicular NHL (a type of low-grade NHL). And because they work to control NHL in different ways, RITUXAN and chemotherapy may work very well together. What we mean by control is less chance of progression, relapse, or death.

In a study, patients who had CVP chemotherapy alone had follicular non-Hodgkin's lymphoma in control for an average of 1.4 years. Control was extended to an average of 2.4 years in those who had RITUXAN plus CVP chemotherapy.

RITUXAN, in combination with CVP chemotherapy, was tested as an initial treatment in a large study. One group received RITUXAN plus CVP chemotherapy. A second group received just CVP chemotherapy.

The study showed that, for many patients, RITUXAN plus CVP chemotherapy was effective at increasing progression-free survival. That means it helped control follicular NHL by significantly shrinking tumors or stopping them from getting worse. And it kept them that way for longer. In fact, 1.7 times longer than in patients who received just CVP chemotherapy.

Remember that results may be different for different people. Read the Medication Guide for a summary of the most important information about RITUXAN. Be sure to ask your oncologist which treatment options are right for you.

RITUXAN® is indicated for the treatment of patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy

*CVP: cyclophosphamide, vincristine, and prednisone or prednisolone

 

Ongoing Therapy

INDICATIONS

RITUXAN^® (rituximab) is indicated for the treatment of patients with:

• Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent
• Previously untreated follicular, CD20-positive, B-cell NHL in combination with CVP chemotherapy
• Non-progressing (including stable disease), low-grade, CD20-positive B-cell NHL, as a single agent, after first-line CVP chemotherapy
• Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens

IMPORTANT SAFETY INFORMATION

RITUXAN can cause serious side effects, some of which can be life-threatening, including: Progressive Multifocal Leukoencephalopathy (PML), infusion reactions, Tumor Lysis Syndrome (TLS), and severe skin reactions. Other serious and life-threatening side effects with RITUXAN include: hepatitis B virus reactivation, heart problems, infections, and stomach and bowel problems. Common side effects during RITUXAN infusions include: fever, headache, chills and shakes, nausea, itching, hives, cough, sneezing, and throat irritation or tightness.

Tell your doctor about any side effects that bother you or that do not go away. These are not all of the possible side effects with RITUXAN. Ask your doctor for more information.

Please read the Medication Guide in HTML or PDF versions for more information.